Healthcare Analysts hold a conference call with CEO Goldsmith on October 3 at 1 pm hosted by JPMorgan.Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines participate in a conference call with JPMorgan
- Revolution Medicines price target raised to $47 from $37 at Stifel
- Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
- Revolution Medicines doses first patient in Phase 1/1b trial of RMC-9805
- JPMorgan ups Revolution Medicines target, adds to Analyst Focus List